Charles River Laboratories International (NYSE:CRL) Cut to “Hold” at Wall Street Zen

Wall Street Zen downgraded shares of Charles River Laboratories International (NYSE:CRL) from a buy rating to a hold rating in a report released on Saturday morning.

Several other research firms have also commented on CRL. Bank of America raised Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 price target on the stock in a research report on Monday, December 15th. Mizuho cut their target price on shares of Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating on the stock in a report on Friday. Barclays decreased their price target on shares of Charles River Laboratories International from $215.00 to $200.00 and set an “overweight” rating for the company in a research note on Thursday. Morgan Stanley set a $185.00 price objective on shares of Charles River Laboratories International in a research report on Monday, December 1st. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Charles River Laboratories International in a report on Wednesday, January 21st. Ten analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $205.77.

Charles River Laboratories International Stock Down 3.4%

Shares of CRL opened at $163.12 on Friday. The company’s 50-day simple moving average is $199.67 and its 200-day simple moving average is $179.72. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.02 and a current ratio of 1.29. Charles River Laboratories International has a 1 year low of $91.86 and a 1 year high of $228.88. The stock has a market capitalization of $8.03 billion, a PE ratio of -55.11, a P/E/G ratio of 3.16 and a beta of 1.63.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, February 18th. The medical research company reported $2.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.33 by $0.06. The business had revenue of $994.23 million for the quarter, compared to analysts’ expectations of $986.98 million. Charles River Laboratories International had a positive return on equity of 15.60% and a negative net margin of 3.59%.The company’s revenue for the quarter was down .8% compared to the same quarter last year. During the same period last year, the firm earned $2.66 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. Analysts forecast that Charles River Laboratories International will post 9.36 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Charles River Laboratories International

Several institutional investors have recently modified their holdings of CRL. Kera Capital Partners Inc. lifted its holdings in shares of Charles River Laboratories International by 4.5% in the fourth quarter. Kera Capital Partners Inc. now owns 2,511 shares of the medical research company’s stock valued at $529,000 after purchasing an additional 108 shares in the last quarter. Compound Planning Inc. raised its position in shares of Charles River Laboratories International by 19.6% during the 4th quarter. Compound Planning Inc. now owns 1,668 shares of the medical research company’s stock worth $333,000 after purchasing an additional 273 shares during the last quarter. Invesco Ltd. lifted its stake in Charles River Laboratories International by 115.8% in the 4th quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company’s stock valued at $537,828,000 after buying an additional 1,446,972 shares in the last quarter. Corient Private Wealth LLC grew its holdings in Charles River Laboratories International by 236.2% during the 4th quarter. Corient Private Wealth LLC now owns 35,170 shares of the medical research company’s stock valued at $7,016,000 after buying an additional 24,708 shares during the last quarter. Finally, Mercer Global Advisors Inc. ADV increased its position in Charles River Laboratories International by 1.3% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 6,316 shares of the medical research company’s stock worth $1,260,000 after buying an additional 80 shares in the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.